FcRn: the neonatal Fc receptor comes of age

By D. Roopenian, Shreeram Akilesh. 2007

2,255 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Baty
2. M. H. V. Van Regenmortel
3. Etienne Weiss
4. M. Kinder
5. P. Carter
6. P. Chames

In Molecular Biology

1. A. Chan
2. D. Baty
3. M. H. V. Van Regenmortel
4. Etienne Weiss
5. D. Richardson
6. D. Kalinowski
7. P. Carter
8. P. Chames

In Radiology, Nuclear Medicine and Imaging

1. A. Chan
2. D. Baty
3. Z. An
4. M. H. V. Van Regenmortel
5. Etienne Weiss
6. K. Howard
7. M. Kuhlmann
8. M. L. Hvam

Citations in the corpus

• Albumin-based drug delivery: harnessing nature to cure disease (2016, background): “FcRn is distributed in many tissues including vascular endothelium as well as the gut, lungs and kidney [63].”
• Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions* (2013, background): “Fc binding to FcRn occurs proximal to the junction of the CH2 and CH3 regions (49), a region that is distal from themutations present in all of the protease-resistant variants.”
• Therapeutic antibodies: successes, limitations and hopes for the future (2009, positive): “…Fc receptor (FcRn) expressed at the surface of several cell types, including vascular endothelium cells, monocytes and macrophages as well as with barrier sites such as the blood–brain interface, the glomerular filter in the kidneys and the intestinal epithelium (Roopenian and Akilesh, 2007).”
• Unraveling the mysteries of serum albumin—more than just a serum protein (2014, background): “Considering the enhanced permeation and retention effect and the accumulation of albumin in the tumor interstitium, the development of albumin as a drug carrier is increasingly important to consider in terms of the targeted delivery of cancer therapy (Kratz, 2008, 2010).”
• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “The interaction between the Fc region of IgG and the recycling receptor FcRn has a key role in IgG homeostasis and is largely responsible for the long half-life of Ig”
• IgG Placental Transfer in Healthy and Pathological Pregnancies (2011, background): “FcRn is also expressed in many other tissues in the adult animal, including barrier sites such as the blood-brain interface, the glomerular filter in the kidneys and the intestinal epithelium, where its function of modulating IgG transport to promote host defense or to control immune-complex deposit”
• Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge (2009, background): “FcRn engages IgGs at a different site than Fc Rs (18) and extends their circulating lifespans by recycling IgGs through endothelial cells (14–16, 18).”
• IgG2m4, an engineered antibody isotype with reduced Fc function (2009, background): “In addition, FcRn binding mediated by the Fc domain plays an important role in the antibody’s half life.(3-5) For therapeutic mAbs that are marketed or in development, IgG is the overwhelming choice as the backbone of the drug molecule.”